FDA
-
-
-
-
-
-
-
Theratechnologies (THTX) announces FDA approval of EGRIFTA WR
-
-
-
-
-
-
-
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
-
-
-
-
-
-
-
Theratechnologies (THTX) Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
-
-
-
-
-
-
-
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
-
-
-
-
-
-
-
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
-
-
-
-
-
-
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
-
-
-
-
-
-
Theratechnologies (THTX) Announces FDA Approval of Trogarzo
-
322,243 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

